S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack

CymaBay Therapeutics (CBAY) Stock Forecast & Price Target

$32.23
+0.04 (+0.12%)
(As of 03/1/2024 ET)

CymaBay Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$27.14
-15.80% Downside
High Forecast$32.50
Average Forecast$27.14
Low Forecast$12.00
TypeCurrent Forecast
3/3/23 to 3/2/24
1 Month Ago
2/1/23 to 2/1/24
3 Months Ago
12/3/22 to 12/3/23
1 Year Ago
3/3/22 to 3/3/23
Consensus Rating
Hold
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
2 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
4 Buy rating(s)
Hold
11 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$27.14$22.64$22.27$12.71
Predicted Upside-15.80% Downside58.79% Upside61.88% Upside114.50% Upside
Get CymaBay Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.


CBAY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CBAY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CymaBay Therapeutics Stock vs. The Competition

TypeCymaBay TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.15
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside-15.80% Downside1,806.21% Upside6.75% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/29/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$32.50+0.71%
2/20/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$32.50+0.99%
2/14/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Jubinville
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
2/14/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.50+1.18%
2/14/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral$25.00 ➝ $32.50+1.18%
2/13/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral
2/13/2024Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
2/13/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Kluska
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$32.50+0.90%
2/13/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral$29.00 ➝ $32.50+0.90%
2/13/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$32.50+0.90%
2/12/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hsieh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/11/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$20.00+54.32%
3/7/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$10.00 ➝ $12.00+33.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:05 PM ET.












CBAY Price Target - Frequently Asked Questions

What is CymaBay Therapeutics's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Hold based on the current 11 hold ratings and 2 buy ratings for CBAY. The average twelve-month price prediction for CymaBay Therapeutics is $27.14 with a high price target of $32.50 and a low price target of $12.00. Learn more on CBAY's analyst rating history.

Do Wall Street analysts like CymaBay Therapeutics more than its competitors?

Analysts like CymaBay Therapeutics less than other Medical companies. The consensus rating for CymaBay Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how CBAY compares to other companies.

Is CymaBay Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, CymaBay Therapeutics's stock had 5 downgrades by analysts.

Does CymaBay Therapeutics's stock price have much upside?

According to analysts, CymaBay Therapeutics's stock has a predicted upside of 4.03% based on their 12-month stock forecasts.

What analysts cover CymaBay Therapeutics?

Stock Ratings Reports and Tools

This page (NASDAQ:CBAY) was last updated on 3/2/2024 by MarketBeat.com Staff